European Journal of Internal Medicine
Volume 19, Issue 7 , Pages 476-481 , November 2008

Venous and arterial thrombosis: Different sides of the same coin?

  • Massimo Franchini

      Affiliations

    • Transfusion and Hemophilia Center, City Hospital of Verona, Italy
    • ,
  • Pier Mannuccio Mannucci

      Affiliations

    • Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialities, University of Milan and IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy
    • Corresponding Author InformationCorresponding author. Via Pace 9, 20122 Milano, Italy. Tel.: +0039 02 55035423; fax: +0039 02 50320723.

Received 12 September 2007 ,Accepted 1 October 2007.

References 

  1. Walker ID, Greaves M, Preston FE. Investigation and management of heritable thrombophilia. Br J Haematol. 2001;114:512–528
  2. Prandoni P. Links between arterial and venous disease. J Intern Med. 2007;262:341–350
  3. Jeries-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease?. Eur Heart J. 2005;26:3–4
  4. Agnelli G, Becattini C. Venous thromboembolism and atherosclerosis: common denominators or different diseases?. J Thromb Haemost. 2006;4:1886–1890
  5. Lowe GDO. Arterial disease and venous thrombosis: are they related, and if so, what should we do about it?. J Thromb Haemost. 2006;4:1882–1885
  6. Prandoni P. Venous thromboembolism and atherosclerosis: is there a link?. J Thromb Haemost. 2007;5(Suppl. 1):270–275
  7. Heit J. Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Haemost. 2002;28(Suppl 2):3–13
  8. Marmot M. Social determinants of health inequalities. Lancet. 2005;365:1099–1104
  9. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–952
  10. Lowe GDO, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol. 1997;97:775–784
  11. Rumley A, Emberson JR, Wannamethee SG, Lennon L, Whincup PH, Lowe GD. Effects of older age on fibrin D-dimer, C-reactive protein, and other hemostatic and inflammatory variables in men aged 60–79 years. J Thromb Haemost. 2006;4:982–987
  12. Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity. Risk factors for VTE among middle aged men: “The study of men born in 1913”. Arch Intern Med. 1999;159:1886–1890
  13. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277:642–645
  14. Deguchi H, Pecheniuk N, Elias D, Averell P, Griffin J. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation. 2005;112:893–899
  15. Eichinger S, Pecheniuk NM, Hron G, et al. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation. 2007;115:1609–1614
  16. Vaya A, Mira Y, Ferrando F, et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol. 2002;118:255–259
  17. Marcucci R, Liotta AA, Cellai AP, et al. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med. 2003;115:601–605
  18. Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:1070–1075
  19. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med. 2005;118:978–980
  20. Hong C, Zhu F, Du D, Pilgram TK, Sicard GA, Bae KT. Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis. 2005;183:169–174
  21. Ageno W, Prandoni P, Romualdi E, et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost. 2006;4:1914–1918
  22. Ay C, Tengler T, Vormittag R, et al. Venous thromboembolism — a manifestation of the metabolic syndrome. Haematologica. 2007;92:374–380
  23. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis. 2005;181:101–108
  24. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611–2618
  25. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006;367:1075–1079
  26. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J. 2003;146:948–957
  27. Ye Z, Liu AHC, Higgins JPT, et al. Seven hemostatic gene polymorphisms in coronary disease: meta-analysis of 66155 cases and 91307 controls. Lancet. 2006;367:651–658
  28. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Schlomo , Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation. 2005;112:3080–3087
  29. Vormittag R, Vukovich T, Stain M, Lehr S, Minar E, Pabinger I. Lipoprotein(a) in patients with spontaneous venous thromboembolism. Thromb Res. 2007;120:15–20
  30. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence. Arch Intern Med. 2002;162:1182–1189
  31. Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol. 2005;162:975–982
  32. Libertiny G, Hands L. Deep venous thrombosis in peripheral vascular disease. Br J Surg. 1999;86:907–910
  33. Eliasson A, Bergqvist D, Bjorck M, Acosta S, Sternby NH, Orgen M. Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23,796 consecutive autopsies. J Thromb Haemost. 2006;4:1897–1902
  34. Reich LM, Folsom AR, Key NS, et al. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost. 2006;4:1909–1913
  35. van der Hagen PB, Folsom AR, Jenny NS, et al. Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost. 2006;4:1903–1908
  36. Prandoni P, Bilora F, Marchiori A, et al. An association between atheroslerosis and venous thrombosis. N Engl J Med. 2003;348:1435–1441
  37. Becattini C, Agnelli G, Prandoni P, et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J. 2005;26:77–83
  38. Prandoni P, Ghirarduzzi A, Prins MH, et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost. 2006;4:1891–1896
  39. Bova C, Marchiori A, Noto A, et al. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study. Thromb Haemost. 2006;96:132–136
  40. Schulman S, Lindmarker P, Holmstrom M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4:734–742
  41. Sorensen HT, Horvath-Puko E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalization due to acute arterial cardiovascular events: a 20 year cohort study. Lancet. 2007;370:1773–1779
  42. Lowe GDO. Fibrin D-dimer and risk of cardiovascular events. Semin Vasc Med. 2005;5:387–398
  43. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001;161:1405–1410
  44. Collaborative overview of randomised trials of antiplatelet therapy — III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308(6923):235–246
  45. The ESPS 2 Group . European Stroke prevention study 2. Efficacy and safety data. Secondary endpoints. J Neurol Sci. 1997;151:S27–S37
  46. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ. 2002;324:71–86
  47. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–124
  48. De Caterina R, Husted S, Wallentin L, et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J. 2007;28:880–913
  49. Phillips DR, Conley PB, Sinha U, Andre P. Therapeutic approaches in arterial thrombosis. J Thromb Haemost. 2005;3:1577–1589
  50. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27:519–526
  51. Anand S, Yusuf S. Oral anticoagulants in patients with coronary artery disease. JACC. 2003;41(Suppl.):62S–69S
  52. The medical research council's general practice research framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet. 1998;351:233–241
  53. Cannon CP. Evolving management of ST-segment elevation myocardial infarction: update on recent data. Am J Cardiol. 2006;98:Q10–Q21(Suppl)
  54. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:576S–599S
  55. Gubitz G, Sandercock P, Counsell C. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev. 2004;3:CD000024
  56. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38:423–430
  57. Aguilar RI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;3:CD006186
  58. Adams HP, Del Zoppo G, Alberts MJ, et al. American Heart Association American Stroke Association Stroke Council Clinical Cardiology Council Cardiovascular Radiology and Intervention Council Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;28:1655–1711
  59. WAVE Investigators . The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. Am Heart J. 2006;151:1–9
  60. WAVE Investigators . Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217–227

PII: S0953-6205(08)00049-6

doi: 10.1016/j.ejim.2007.10.019

European Journal of Internal Medicine
Volume 19, Issue 7 , Pages 476-481 , November 2008

Article Tools